Assessing the Predictive Capability of ctDNA as a Screening Tool for Ovarian Cancer

Cancer
Jill Tseng
Assessing the Predictive Capability of Circulating Tumor DNA (ctDNA) as a Screening Tool for Ovarian Cancer
Ovary

Study Description

Eligibility

-Women ages 18 and older.

-Willing to undergo germline mutation testing as would be recommended within

routine clinical care.

-Undergoing RRSO or removal of an adnexal (ovarian or fallopian tube mass) within

routine clinical care

-Prior invasive malignancy other than squamous or basal cell carcinomas of the

skin or in situ cervical cancer

-Prior systemic chemotherapy or pelvic radiation treatment

-Germ cell and sex-cord stromal cell carcinomas on final pathologic evaluation will

not have prospective tissue preparation for DNA isolation and will be excluded

from additional analysis.

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.